Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GATT gives time to develop more generic products -- PRI tells analysts.

Executive Summary

GATT PATENT EXTENSIONS MAY GIVE PAR TIME TO DEVELOP MORE GENERIC products, Pharmaceutical Resources, Inc. CEO Kenneth Sawyer told analysts at the Dillon, Read Generic Drug & Drug Delivery Conference May 11 in New York City. The redefined patent terms under the General Agreement on Tariffs & Trade give "us a lag of another, on average, year or 18 months....It really does help our company in that it gives us the time to generate more and more of those products that are difficult to manufacture and bring to the market," Sawyer said.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS026186

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel